Trial
NCT05125679
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Janssen-Cilag Ltd.
Collaborators
—
Condition
Psoriasis
Intervention
Guselkumab
Why stopped
Terminated (A strategic decision was made not to further execute the study. This decision was not based on a safety concern)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-30